Binimetinib

• Tablets 15mg

Notes

1. NICE TA562: Encorafenib (Braftovi) with binimetinib (Mektovi) is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides encorafenib and binimetinib according to the commercial arrangements (February 2019).

Selumetinib

• Capsules 10mg, 25mg

Notes

1. NICE HST20: Selumetinib (Koselugo) is recommended, within its marketing authorisation, for treating symptomatic and inoperable plexiform neurofibromas (PN) associated with type 1 neurofibromatosis (NF1) in children aged 3 and over, only if the company provides selumetinib according to the commercial arrangement (May 2022).

Trametinib

• Tablets 2mg
• Oral solution sugar free 50micrograms/ml

Notes

1. NICE TA396: Trametinib (Mekinist) in combination with dabrafenib (Tafinlar) is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes (June 2016).
2. NICE TA544: Dabrafenib (Trafinlar) with Trametinib (Mekinst) is recommended, within its marketing authorisation, as an option for the adjuvant treatment of resected stage III, BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides dabrafenib and trametinib with the discounts agreed in the commercial arrangements (October 2018).
3. NICE TA977: Dabrafenib (Finlee) with trametinib (Spexotras) is recommended, within its marketing authorisation, as an option for treating:
   1. low-grade glioma (LGG) with a BRAF V600E mutation in children and young people aged 1 year and over who need systemic treatment
   2. high-grade glioma (HGG) with a BRAF V600E mutation in children and young people aged 1 year and over after at least 1 radiation or chemotherapy treatment.
   3. Only if the company provides it according to the commercial arrangements (May 2024).
4. MHRA Drug Safety Update (March 2016): Trametinib (Mekinist): risk of gastrointestinal perforation and colitis.

Cobimetinib

• NICE TA414: Cobimetinib (Cotellic) in combination with vemurafenib is not recommended within its marketing authorisation for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation (October 2016).